NCT04737304 is a Phase 1, PHASE2 clinical trial of BEN2293 (0.25% or 1.0% w/w) or matching placebo in Atopic Dermatitis, sponsored by BenevolentAI Bio.

Who is sponsoring NCT04737304?

NCT04737304 is sponsored by BenevolentAI Bio.

What drugs are being tested in NCT04737304?

Interventions in NCT04737304: BEN2293 (0.25% or 1.0% w/w) or matching placebo.

What condition does NCT04737304 study?

NCT04737304 studies Atopic Dermatitis.

Is NCT04737304 still recruiting?

NCT04737304 is currently completed. Last updated 18 June 2023.

Last reviewed 2023-06-18 · How we verify

NCT04737304

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis

Completed Phase 1, PHASE2 Last updated 18 June 2023

What this trial tests

Phase 1, PHASE2 trial testing BEN2293 (0.25% or 1.0% w/w) or matching placebo in Atopic Dermatitis in 123 participants. Completed in 26 January 2023.

Timeline

14 October 2020

Primary endpoint
12 January 2023

26 January 2023

Quick facts

Lead sponsor	BenevolentAI Bio
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	123
Start date	14 October 2020
Primary completion	12 January 2023
Estimated completion	26 January 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

BEN2293 (0.25% or 1.0% w/w) or matching placebo — full drug profile →

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

BenevolentAI Bio — full company profile →

Who can join

Adults 18 to 65, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomised, adaptive design, double-blind, placebo-controlled, first-in-human, two-part study to investigate the safety, tolerability, PK and preliminary efficacy of multiple topical doses of BEN2293 in patients with mild to moderate AD.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.
Bieber T. · · 2022 · cited 421× · PMID 34417579 · DOI 10.1038/s41573-021-00266-6
What's New in Topicals for Atopic Dermatitis?
Kleinman E, Laborada J, Metterle L, Eichenfield LF. · · 2022 · cited 50× · PMID 36048410 · DOI 10.1007/s40257-022-00712-0
New and Upcoming Topical Treatments for Atopic Dermatitis: A Review of the Literature.
Sideris N, Paschou E, Bakirtzi K, Kiritsi D, et al · · 2022 · cited 28× · PMID 36078904 · DOI 10.3390/jcm11174974
The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges.
Chakraborty C, Bhattacharya M, Lee SS, Wen ZH, et al · · 2024 · cited 25× · PMID 39257717 · DOI 10.1016/j.omtn.2024.102295
Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, Steele L, et al · · 2024 · cited 22× · PMID 39105474 · DOI 10.1002/14651858.cd015064.pub2
The future of pharmaceuticals: Artificial intelligence in drug discovery and development.
Fu C, Chen Q. · · 2025 · cited 18× · PMID 40893437 · DOI 10.1016/j.jpha.2025.101248
Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis.
Pinto LM, Chiricozzi A, Calabrese L, Mannino M, et al · · 2022 · cited 17× · PMID 36559261 · DOI 10.3390/pharmaceutics14122767
Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
Duffen JL, Crouse KK, Ji L, Brault AL, et al · · 2026 · cited 1× · PMID 41803126 · DOI 10.1038/s41467-026-70000-6

Verify or expand the search:

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other BenevolentAI Bio trials

Trials by the same sponsor.

NCT06118385 — Study Investigating the Safety, Tolerability, PK and Food Effect of BEN8744. · Phase 1 · completed
NCT03194217 — BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04737304 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BenevolentAI Bio
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04737304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing